DK1464331T3 - Komprimeret, oral, farmaceutisk doseringsform med en enterisk coating, der indeholder en syrelabil benzimidazolforbindelse - Google Patents

Komprimeret, oral, farmaceutisk doseringsform med en enterisk coating, der indeholder en syrelabil benzimidazolforbindelse

Info

Publication number
DK1464331T3
DK1464331T3 DK02785447T DK02785447T DK1464331T3 DK 1464331 T3 DK1464331 T3 DK 1464331T3 DK 02785447 T DK02785447 T DK 02785447T DK 02785447 T DK02785447 T DK 02785447T DK 1464331 T3 DK1464331 T3 DK 1464331T3
Authority
DK
Denmark
Prior art keywords
dosage form
pharmaceutical dosage
acid
enteric coating
benzimidazole compound
Prior art date
Application number
DK02785447T
Other languages
Danish (da)
English (en)
Inventor
Garcia Javier Lizcano
Perez Jaume Sangra
Ibarra Pere Joan Solanas
Cabrera Antonio Lopez
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Application granted granted Critical
Publication of DK1464331T3 publication Critical patent/DK1464331T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK02785447T 2001-12-18 2002-11-18 Komprimeret, oral, farmaceutisk doseringsform med en enterisk coating, der indeholder en syrelabil benzimidazolforbindelse DK1464331T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200102820A ES2198195B1 (es) 2001-12-18 2001-12-18 Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
PCT/ES2002/000536 WO2003051342A1 (es) 2001-12-18 2002-11-18 Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido

Publications (1)

Publication Number Publication Date
DK1464331T3 true DK1464331T3 (da) 2009-01-05

Family

ID=8499777

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02785447T DK1464331T3 (da) 2001-12-18 2002-11-18 Komprimeret, oral, farmaceutisk doseringsform med en enterisk coating, der indeholder en syrelabil benzimidazolforbindelse

Country Status (19)

Country Link
US (1) US7217429B2 (ja)
EP (1) EP1464331B9 (ja)
JP (1) JP4523278B2 (ja)
KR (1) KR100877649B1 (ja)
AT (1) ATE410149T1 (ja)
AU (1) AU2002350750B2 (ja)
CA (1) CA2470609C (ja)
DE (1) DE60229295D1 (ja)
DK (1) DK1464331T3 (ja)
ES (2) ES2198195B1 (ja)
HR (1) HRP20040596A2 (ja)
HU (1) HUP0402488A3 (ja)
IL (2) IL162544A0 (ja)
MX (1) MXPA04005902A (ja)
NO (1) NO20042630L (ja)
NZ (1) NZ533886A (ja)
PT (1) PT1464331E (ja)
WO (1) WO2003051342A1 (ja)
ZA (1) ZA200405078B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
ES2278511B1 (es) * 2005-07-28 2008-06-16 Laboratorios Almirall S.A. Comprimidos con perfil de disolucion mejorado.
WO2007100984A2 (en) * 2006-02-24 2007-09-07 Allergan, Inc. Beads containing pyridin-sulfinyl benzoimidazole sulfonyl phenoxy acetate derivatives
US8377475B2 (en) * 2009-01-05 2013-02-19 Mcneil-Ppc, Inc. Tablet containing cetirizine, pseudoephedrine, and naproxen containing a barrier layer
US8252330B2 (en) * 2009-01-05 2012-08-28 Mcneil-Ppc, Inc. Tablet containing coated particles of cetirizine, pseudoephedrine, and/or naproxen
US8246988B2 (en) * 2009-01-05 2012-08-21 Mcneil-Ppc, Inc. Three layer tablet containing cetirizine, pseudoephedrine, and naproxen
WO2010117756A2 (en) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Substituted benzimidazole pharmaceutical formulations
EP2345408A3 (en) * 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
EP2595611A2 (en) * 2010-07-22 2013-05-29 Lupin Limited Multiple unit tablet composition
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
PT1078628E (pt) * 1994-07-08 2009-01-27 Astrazeneca Ab Forma de dosagem em comprimidos com unidades múltiplas
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
DE69631981T2 (de) * 1995-09-21 2005-04-14 Pharma Pass Ii Llc, Irvine Lansoprazolhaltige Arzneizusammensetzung und Herstellungsverfahren
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9700885D0 (sv) * 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
JP2002363080A (ja) * 2001-06-08 2002-12-18 Towa Yakuhin Kk 安定な内服用抗潰瘍製剤の製造法

Also Published As

Publication number Publication date
EP1464331B1 (en) 2008-10-08
WO2003051342A1 (es) 2003-06-26
KR100877649B1 (ko) 2009-01-12
ZA200405078B (en) 2005-06-27
HRP20040596A2 (en) 2004-10-31
KR20040079906A (ko) 2004-09-16
AU2002350750A1 (en) 2003-06-30
AU2002350750B2 (en) 2008-10-16
ES2315416T3 (es) 2009-04-01
CA2470609C (en) 2010-09-28
JP2005523884A (ja) 2005-08-11
HUP0402488A2 (hu) 2005-05-30
PT1464331E (pt) 2008-11-19
IL162544A (en) 2010-04-29
DE60229295D1 (de) 2008-11-20
NZ533886A (en) 2005-12-23
US7217429B2 (en) 2007-05-15
ES2198195B1 (es) 2004-10-01
ES2198195A1 (es) 2004-01-16
HUP0402488A3 (en) 2009-09-28
CA2470609A1 (en) 2003-06-26
ATE410149T1 (de) 2008-10-15
JP4523278B2 (ja) 2010-08-11
IL162544A0 (en) 2005-11-20
NO20042630L (no) 2004-08-13
EP1464331B9 (en) 2009-10-14
MXPA04005902A (es) 2004-09-13
US20030118650A1 (en) 2003-06-26
EP1464331A1 (en) 2004-10-06

Similar Documents

Publication Publication Date Title
Huang et al. Pharmacological and pharmacodynamic essentials of H2-receptor antagonists and proton pump inhibitors for the practising physician
JP4818516B2 (ja) 化合物の抗菌剤としての新規な使用
DK1464331T3 (da) Komprimeret, oral, farmaceutisk doseringsform med en enterisk coating, der indeholder en syrelabil benzimidazolforbindelse
EE04800B1 (et) Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks
SE9600071D0 (sv) New oral formulation of two active ingredients I
SE0101379D0 (sv) Komposition som hämmar utsöndring av magsyra
DE69631834D1 (de) Neues ein säureempfindliches benzimidazol enthaltendes mittel und verfahren zu dessen herstellung
ATE334679T1 (de) Feste oral anzuwendende arzneizubereitung mit gesteuerter wirkstoffabgabe enthaltend eine säureempfindliche benzimidazolverbindung
BR0011894A (pt) Forma de dosagem oral, processo para a fabricação de forma de dosagem, uso de forma de dosagem farmacêutica oral, e, métodos para aumentar inibição de secreção do ácido gástrico e para aumentar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com excesso de secreção ácida
SE9804314D0 (sv) New pharmaceutical formulation
HRP20010119B1 (en) Preventing airway mucus production by administration of egf-r antagonists
BR9506028A (pt) Forma farmacêutica oral de múltipla dosagem unitária em tablete processos para a preparação da mesma para a inibição da secreção de ácido gástrico em mamiferos e no homem e para o tratamento das doenças inflamatórias gastrointestinais em mamiíferos e no homem e embalagem de ampola de pressão transversal
DE69909316D1 (de) Pharmazeutische formulierung mit omeprazol
AR038157A1 (es) Formas de dosificacion de benzimidazoles sustituidos y su uso
ME00318B (me) Nova kompozicija i njena upotreba
RU2006118786A (ru) Твердый препарат
DE60220055D1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
WO2002069968A8 (en) New use
FR2845915B1 (fr) Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
IL133216A0 (en) 2-ä4-[4(4,5-Dichloro-2-methylimidazol-1-yl) butyl]-1 piperazinylü-5-fluoropyrimidine preparation and therapeutic use
UA145706U (uk) Фармацевтична композиція
SE8304818D0 (sv) A medicine having anti-ulcer, spasmolytic and locally anesthetic effect
JP2004529893A5 (ja)